Trial Profile
ISIS 2302-CS22, Phase II, Double-Blinded, Active-Controlled Study of Alicaforsen (ISIS 2302) Enema, an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Mild to Moderate Active Ulcerative Colitis (Left-Sided Colitis or Pancolitis With Left Sided Disease Flare)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alicaforsen (Primary) ; Mesalazine
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 07 Jan 2016 New trial record